Source: Aastrom Biosciences, Inc.
Date: October 18, 2007
Summary:
Aastrom Biosciences, Inc, announced final results from a U.S. Phase I/II clinical trial designed to collect safety and efficacy data utilizing Bone Repair Cells (BRCs) in the treatment of severe non-union fractures. In the study, patients with non-union tibia, humerus or femur fractures that had failed to heal after one or more medical procedures showed an overall healing rate of 91% after one year.
